Evidence map›Paper›PMID 39404983›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2025

Pharmacist-facilitated Patient Reported Outcome Measure (PROM) monitoring: developing an EHR SmartForm© to monitor side effects of oral oncolytics during routine telehealth encounters.

Angela M Stover, Debbie Liang, Dana Mueller, Rachel Kurtzman, Christiana Ikemeh, Courtney Canter, Sonali Acharya, Jill Brese, Kaitlyn Buhlinger, Kevin Chen and 14 more

Abstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Angela M StoverDepartment of Health Policy and Management, UNC Chapel Hill, Chapel Hill, NC, USA. stoveram@email.unc.edu.ORCID http://orcid.org/0000-0003-0983-686X
Debbie LiangUNC Health Pharmacy Analytics and Outcomes, Chapel Hill, NC, USA.
Dana MuellerDepartment of Urology, UNC Chapel Hill, Chapel Hill, NC, USA.
Rachel KurtzmanNORC, Chicago, IL, USA.
Christiana IkemehDepartment of Health Policy and Management, UNC Chapel Hill, Chapel Hill, NC, USA.
Courtney CanterNC TraCS, UNC Chapel Hill, Chapel Hill, NC, USA.
Sonali AcharyaUNC Health Specialty Pharmacy, Durham, NC, USA.
Jill BreseUNC Health Specialty Pharmacy, Durham, NC, USA.
Kaitlyn BuhlingerUNC Medical Center Oncology Outpatient Clinics, Chapel Hill, NC, USA.
Kevin ChenUNC Medical Center Oncology Outpatient Clinics, Chapel Hill, NC, USA.
Evan W ColmenaresUNC Medical Center Oncology Outpatient Clinics, Chapel Hill, NC, USA.
Aimee FasoUNC Medical Center Oncology Outpatient Clinics, Chapel Hill, NC, USA.
Benyam MulunehUNC Medical Center Oncology Outpatient Clinics, Chapel Hill, NC, USA.
Bianka PatelUNC Medical Center Oncology Outpatient Clinics, Chapel Hill, NC, USA.
Jeffrey S ReichardDepartment of Pharmacy, UNC Health, Chapel Hill, NC, USA.
Rushabh M ShahUNC Health Specialty Pharmacy, Durham, NC, USA.
Michael TilkensDepartment of Pharmacy, UNC Health, Chapel Hill, NC, USA.
John ValgusDepartment of Pharmacy, UNC Health, Chapel Hill, NC, USA.
Lorinda A CoombsLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA.
Jennifer Elston LafataLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA.
Jennifer L LundLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA.
Emily M RayLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA.
Gita ModyLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA.
Mary-Haston VestUNC Health Pharmacy Analytics and Outcomes, Chapel Hill, NC, USA.

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
Geriatric Oncology Research Infrastructure to Improve Clinical CareR33AG059206 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE, Heidi Diana Klepin · 2020 to 2026
$5.1M
Geriatric Oncology Research Infrastructure to Improve Clinical CareR21AG059206 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DALE, WILLIAM, MOHILE, SUPRIYA G. · 2018 to 2019
$478k
NCATS/NIH UL1TR002489NCATS NIH HHS UL1 TR002489NCATS NIH HHS UM1 TR004406NIA NIH HHS R21 AG059206NIA NIH HHS R21AG059206/R33AG059206NIA NIH HHS R33 AG059206
6 · The paper itself

Abstract

purposePatient reported outcome measures (PROMs) are increasingly used in oncology care, but pharmacists providing direct patient care have been overlooked. We engaged pharmacists and adults receiving oral oncolytics (chemotherapy medication taken by mouth) to develop a SmartForm© in the electronic health record (EHR) for PROM monitoring. Pharmacists verbally ask the patient side effect questions during routine telehealth encounters and enter responses in real time.

methodsOur development process was guided by the Knowledge to Action Framework. In phase 1 (Knowledge Inquiry), we prioritized side effects to assess in the EHR SmartForm© via interviews with patients and a Delphi panel with pharmacists. Adults receiving oral oncolytics for breast (n = 12), thoracic (n = 12), or hematological (n = 12) cancer were interviewed, with purposeful sampling for adults who were aged 65 + years or Black. Interviews were coded with content analysis. We conducted three Delphi rounds, with 11/19, 13/19, and 19/19 pharmacists, respectively. In phase 2 (Knowledge Synthesis), PROM items were selected and the EHR SmartForm© programmed. In phase 3 (Knowledge Tailoring), we conducted usability testing with pharmacists.

resultsPharmacists and patients were consistent in prioritizing side effects of oral oncolytics and 10 were retained. Patients advocated asking whether they can do their usual activities, while pharmacists added medication adherence. Usability testing yielded suggestions to simplify the SmartForm©.

conclusionBy presenting screenshots of our SmartForm©, our findings are useful to other healthcare systems looking for a PROM solution integrated in the EHR, with a reasonable pharmacist/clinician workload, and no requirement for patients to have internet access/comfort.

Indexed as

Antineoplastic AgentsElectronic Health RecordsNeoplasmsPatient Reported Outcome MeasuresPharmacistsTelemedicineAdministration, OralAdultAgedDelphi TechniqueFemaleHumansMaleMiddle AgedAntineoplastic AgentsAntineoplastic chemotherapyClinical pharmacy servicesNeoplasmsOral drug administrationPatient reported outcome measuresQuality of life

Identifiers

PMID39404983
PMCPMC11802710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.